What is the recommended management and treatment for chronic hepatitis B infection?

Management and Treatment of Chronic Hepatitis B Infection

For chronic hepatitis B, first-line treatment should be entecavir or tenofovir monotherapy in patients requiring antiviral therapy, as these agents have the highest potency and genetic barrier to resistance. 1, 2

Treatment Indications

Compensated Cirrhosis

• Treat all patients with HBV DNA ≥2,000 IU/mL regardless of ALT levels 1, 3
• Consider treatment even when HBV DNA <2,000 IU/mL to reduce decompensation risk 1
• Oral antiviral therapy with tenofovir or entecavir is preferred 1
• Peginterferon-α may be used cautiously with careful monitoring in patients with preserved liver function 1

Decompensated Cirrhosis

• Initiate prompt antiviral therapy if HBV DNA is detectable by PCR, regardless of ALT levels 1
• Oral therapy with tenofovir or entecavir is mandatory 1
• Peginterferon-α is absolutely contraindicated due to risk of hepatic failure 1
• Simultaneously evaluate for liver transplantation 1
• Clinical improvement requires 3-6 months, so progression to hepatic failure remains possible during early treatment 1

HBeAg-Positive Chronic Hepatitis

• Treat when HBV DNA ≥20,000 IU/mL with ALT >2× ULN 2, 3
• For patients with HBV DNA ≥20,000 IU/mL but normal ALT: consider liver biopsy or transient elastography, particularly if age >35-40 years; treat if significant disease present 2
• Treatment options: entecavir, tenofovir, or peginterferon alfa-2a 2
• Long-term treatment typically required for oral agents 2

HBeAg-Negative Chronic Hepatitis

• Treat when HBV DNA ≥2,000 IU/mL with elevated ALT 4, 2, 3
• Lower threshold (2,000 IU/mL) compared to HBeAg-positive disease 4, 2
• For normal ALT with HBV DNA ≥2,000 IU/mL: obtain biopsy or elastography; treat if disease present 2, 3
• Long-term antiviral therapy required 4, 2

First-Line Treatment Agents

Preferred Oral Agents

Entecavir and tenofovir are the preferred first-line agents due to:

• Highest potency with >90% virologic remission rates after 3 years in adherent patients 2
• Superior resistance profiles: entecavir shows 1.2% resistance after 5 years; tenofovir shows no resistance after 1.5 years in treatment-naïve patients 4, 2
• Excellent long-term safety profiles 2
• Ability to reverse fibrosis and even cirrhosis with long-term use 2

Peginterferon Alfa-2a

• Finite treatment duration (12 months) 2, 3
• Higher rates of HBeAg seroconversion and HBsAg loss compared to oral agents given for equivalent duration 2
• Major disadvantages: subcutaneous injection, significant side effects, contraindicated in decompensated cirrhosis 2
• Consider in mild-moderate disease without cirrhosis 3

Agents NOT Recommended as First-Line

Lamivudine: High resistance rates with long-term use; reserve for special circumstances (pregnancy, short-term chemoprophylaxis, HIV-HBV coinfection) 4, 2, 5

Adefovir: Inferior antiviral efficacy compared to tenofovir 4, 2

Telbivudine: Moderate resistance rates at 2 years; limited long-term data 4

Treatment Goals

Primary goal: Durable HBV DNA suppression to prevent progression to cirrhosis, liver failure, HCC, and death 4, 2

Secondary goals:

• ALT normalization 2
• Histologic improvement 2
• HBeAg seroconversion in HBeAg-positive patients 2
• Optimal endpoint: HBsAg loss (occurs in <5% at 12 months with current therapies) 2, 6

Monitoring During Treatment

Chronic Hepatitis (HBeAg-positive or negative)

• Normal ALT: Test liver function and HBV DNA by real-time PCR every 2-6 months; check HBeAg status every 6-12 months 1
• Elevated ALT: Test liver function every 1-3 months; measure HBV DNA and check HBeAg status every 2-6 months 1

Compensated Cirrhosis

• Test liver function every 2-6 months 1
• Measure HBV DNA by real-time PCR and check HBeAg status every 2-6 months 1

Decompensated Cirrhosis

• Test liver function every 1-3 months 1
• Measure HBV DNA and check HBeAg status every 2-6 months 1

Special Populations

Pregnancy

• Treat women with HBV DNA ≥10^7 copies/mL and elevated ALT during third trimester to prevent vertical transmission 4
• Lamivudine, telbivudine, or tenofovir are options (pregnancy category B) 4
• Tenofovir or lamivudine preferred due to known safety experience 4
• Women already on treatment can continue or switch to pregnancy-safe agent 4

Immunosuppression/Chemotherapy

• Screen all high-risk patients for HBsAg before initiating immunosuppression 5
• Initiate prophylactic lamivudine at onset of chemotherapy; continue for 6 months after completion 5
• Consider tenofovir for longer-term immunosuppression due to lower resistance 4

Common Pitfalls

Avoid lamivudine as first-line monotherapy except in specific circumstances, as increasing resistance negates initial benefits and can worsen liver disease 5, 4, 2

Do not use peginterferon in decompensated cirrhosis due to risk of precipitating hepatic failure 1, 5, 1

Do not delay treatment in decompensated cirrhosis waiting for ALT elevation or specific HBV DNA thresholds—any detectable HBV DNA warrants immediate treatment 1, 7

Monitor renal function when using tenofovir or adefovir, particularly in patients with pre-existing renal disease or decompensated cirrhosis 5